Astepro® Nasal Spray for COVID-19
(COVID-19 Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
The study team proposes to evaluate the efficacy of Astepro® 0.15% nasal spray in treating SARS-CoV-2 infection in adults through a pilot and feasibility clinical trial at the University of Chicago.
Will I have to stop taking my current medications?
The trial requires that you stop using certain medications, such as other Covid-19 treatments and any intranasal, corticosteroid, or immunomodulator medications that could affect the study drug, Astepro.
How does Astepro® Nasal Spray for COVID-19 differ from other treatments?
Who Is on the Research Team?
Brandon Baird
Principal Investigator
University of Chicago
Are You a Good Fit for This Trial?
This trial is for adults with a positive COVID-19 test who can provide saliva samples every other day for 10 days and report symptoms. Participants should have mild or no symptoms, be able to follow study instructions, and not use other COVID treatments during the study. Vaccinated individuals are eligible.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants receive Astepro® 0.15% nasal spray or placebo for 10 days to manage Covid-19 symptoms and assess viral load
Follow-up
Participants are monitored for safety and effectiveness after treatment, including assessment of Covid-19 infectivity in close contacts
What Are the Treatments Tested in This Trial?
Interventions
- Experimental
- Placebo Comparator
Find a Clinic Near You
Who Is Running the Clinical Trial?
University of Chicago
Lead Sponsor